

Date of the conference: June 13th, 2024

Title: “Update on ACS: The Past, Present, and Future”

Date of online publication: June 18th, 2024

Expiry date: March 17th, 2025

Objectives: At the end of this activity, the participant will be able to:

Learning Objectives:

1) Historical Context and contributions:

Understand the foundational work and landmark trials in the management of Acute Coronary Syndrome (ACS), and recognize how these early studies have shaped current standard of care.

2) Current Approaches and Outcomes in ACS Management:

Describe the current standards of care in ACS, focusing on contemporary antiplatelet therapies, outcomes, and best practices. Evaluate recent advancements that have influenced today's therapeutic strategies.

3) Future Directions and Emerging Therapies:

Explore emerging research and future directions in ACS management, including the potential impact of novel therapies such as Factor XI inhibitors (FXI), anti-inflammatory agents, and advanced LDL-lowering agents. Identify research opportunities aimed at further improving care and outcomes in the ACS patient population.

Target Audience

Cardiologists, cardiac surgeons, anesthesiologists, internists, residents and other health professionals working in the cardiovascular field

Speaker

Dre Roxana Mehran, Director of Interventional Cardiovascular Research and Clinical Trials, Cardiovascular Institute at Mount Sinai School of Medicine NY USA

Conflicts of interest

Dr. Mehran reports institutional research payments from:

Abbott, Abiomed, Affluent Medical, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, AtriCure Inc., Biotronik, Boston Scientific, Bristol-Myers Squibb,



CardiaWave, CeloNova, CERC, Chiesi, Concept Medical, Cordis, Daiichi Sankyo, Duke, Element Science, Essential Medical, Faraday, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Population Health Research Institute, Protembis, RecCor Medical Inc., RenalPro, RM Global, Sanofi, Shockwave, Vivasure, Zoll ;

Personal fees from:

Affluent Medical, Boehringer Ingelheim, Cardiovascular Research Foundation (CRF), Daiichi Sankyo Brasil, Esperion Science/Innovative Biopharma, Europa Group/Boston Scientific, Gaffney Events Educational Trust, Global Clinical Trial Partners, Ltd., Henry Ford Health Cardiology, Ionis Pharmaceuticals, IQVIA, Lilly and Company, MedCon International, Novartis, NovoNordisk, PeerView Institute for Medical Education, Radcliffe, TARSUS Cardiology, TERUMO Europe N.V., Vectura, VoxMedia, WebMD ;

No Fees from:

AMA (Scientific Advisory Board),
SCAI (Women in Innovations Committee Member),
Faculty CRF ;

Honorarium:

JAMA Cardiology (Associate Editor),
ACC (BOT Member, SC Member CTR Program) ;

Equity <1% in:

Elixir Medical,
STEL,
ControlRad (spouse)

Accreditation

This activity is an accredited group training activity (section 1) within the meaning of the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada as well as a recognized professional development activity (Category A) as defined by the College of Physicians of Quebec.

The Continuing Professional Development Department (DDPC) of the Federation of Medical Specialists of Quebec has approved this activity.

You can declare a maximum of 1 hour in section 1 / recognized professional development activity (Category A). Participants must claim a number of hours consistent with the duration of their participation.





**INSTITUT DE
CARDIOLOGIE**
DE MONTRÉAL

Université 
de Montréal

Scientific Committee

Dr Serge Doucet, Cardiology, Hemodynamics, Director of Education

Dr. Carmen Baltazar, Emergency physician, Head of emergency education

Mrs. Dominique Trudel, Assistant to the Director of Education

Mr. Julien Le Van, Pharmacist, Head of pharmacy education



**INSTITUT DE
CARDIOLOGIE**
DE MONTRÉAL

AFFILIÉ À
Université 
de Montréal